Table 3.

Change in serum phosphorus level from baseline to end of stage 1 in the sucroferric oxyhydroxide group by age group (FAS population; N = 65)

Parameter	Age ≥ 2 to < 6 years (n = 6)	Age ≥ 6 to < 12 years (n = 17)	Age ≥ 12 to ≤ 18 years (n = 42)
Baseline
Mean ± SD, mg/dL	7.33 ± 1.992	6.93 ± 1.883	6.12 ± 1.522
End of stage 1
Mean ± SD, mg/dL	7.09 ± 1.924	6.21 ± 2.730	5.61 ± 1.578
Change from BL to stage 1
Mean ± SD	− 0.24 ± 0.783	− 0.72 ± 2.136	− 0.51 ± 1.291
Pre-defined modela
LS mean ± SE	− 0.243 ± 0.380	− 0.620 ± 0.489	− 0.460 ± 0.192
95% CI	− 1.450, 0.965	− 1.675, 0.436	− 0.850, − 0.070
p valueb	0.568	0.227	0.022
Post hoc modelc
LS mean ± SE   95% CI   p valueb	− 0.243 ± 0.405 − 1.986, 1.501 0.610	− 0.608 ± 0.498 − 1.694, 0.478 0.246	− 0.460 ± 0.195 − 0.856, − 0.065 0.024

BL, baseline; CI, confidence interval; FAS, full analysis set; LS, least squares; SD, standard deviation; SE, standard error

^aResults are obtained from a linear mixed model that includes change in serum phosphorus levels from baseline to the end of stage 1 as dependent variable and treatment, baseline serum phosphorus, age (in categories) at randomization, region (non-US/US), and gender as fixed effects (pre-defined statistical model)

^bp value for least squares means t test is presented

^cResults are obtained from a linear mixed model which includes change in serum phosphorus levels from baseline to the end of stage 1 as dependent variable and treatment, baseline serum phosphorus, age at randomization, region (non-US/US), and gender as fixed effects (post hoc analysis)